What are the recommendations for oral antiplatelet therapy at hospital discharge for patients with NSTE-ACS?
At hospital discharge, patients with NSTE-ACS should receive an oral antiplatelet agent, such as aspirin, clopidogrel, or a combination of the two medications. It is recommended that dual antiplatelet therapy be used for at least 12 months for patients with NSTE-ACS who have been treated with a percutaneous coronary intervention (PCI). For patients who do not receive PCI, it is recommended that antiplatelet therapy be continued for at least 6 months.